NATH — Nathan's Famous, Inc. · 2026-09-11 · Verdict: PASS · Conviction 4
Price $97.81 (screen row, 2026-09-11 run) · Mkt cap $401M · EV $424M · EV/normalised EBIT 12.7x · FCF yield 4.5% · Net debt $22.9M · ADV $2.5M Sources read: 10-K 2026-06-09 (Items 1, 1A, 7), 10-Q 2026-08-07, DEF 14A 2025-07-25, 8-Ks 2026-06-09 and 2026-08-07, Form 4s (12m). No call transcript or prepared remarks were filed as an exhibit; the EX-99.1 earnings release is the closest SEC-sourced substitute.
Desk stats - Revenue trend: FY2026 (52 weeks to 2026-03-29) revenue $162.063M versus $148.182M, up 9.4%. Almost all of it is beef price pass-through: Branded Product Program sales rose 15% to $105.768M on a 12% higher average selling price and 1% more volume, while license royalties were flat at $37.417M and Company-owned restaurant sales fell 2% on a 2% traffic decline (10-K 2026, Item 7). Q1 FY2027 revenue $54.062M, up 15.0% year over year, again on price: Branded Product up 20% on a 17% price increase and 8% volume, licensing up 10% (8-K 2026-08-07). - Normalised after-tax operating profit: FY2026 GAAP operating income $30.102M (8-K 2026-06-09). The only adjustment I can support is merger transaction costs of $3.210M, being legal, accounting and advisory fees on the Smithfield deal, taken out in the company's own Adjusted EBITDA bridge (10-K 2026, Item 7). There were no impairments: the 10-K states no long-lived assets and no intangible assets were impaired in FY2026 or FY2025. Normalised operating income is therefore $33.312M, or $24.98M taxed at 25%, against GAAP $30.102M. On a trailing twelve months basis through Q1 FY2027 the same treatment gives $33.484M normalised, $25.11M after tax. - EV / normalised after-tax profit: 17.0x on FY2026, 16.9x on trailing twelve months. EV is 4,097,661 shares at $97.81 ($400.79M) plus term loan debt of roughly $47.6M (tagged non-current long-term debt of $45.161M at 2026-06-28 plus the $2.4M a year of mandatory amortisation implied by the $600K quarterly financing outflow in the 10-Q) less cash of $24.686M, so $423.7M. - Leverage: net debt $22.9M / normalised EBITDA $34.2M (normalised EBIT $33.312M plus D&A $0.925M) = 0.67x. The five-year unsecured Citibank facility, drawn $60M in July 2024, matures 2029-07-10 (10-K 2026, Item 7). Book equity is negative $7.2M, a legacy of buybacks and dividends, not distress. - Is the growth sustainable? No, and it does not matter. The revenue growth is beef inflation passed through at a lower gross margin: Branded Product segment operating income fell 42% to $1.330M in Q1 FY2027 as the cost per pound of hot dogs rose 22% (8-K 2026-08-07). Consolidated FY2026 gross profit fell to $11.757M, 10% of sales, from $14.835M, 14% (10-K 2026, Item 7). There is no guidance because the company is being acquired. - What the screen got wrong: everything that matters. The screen row carries no merger flag, so it values a company whose equity has been contractually capped at $102.00 a share in cash since 2026-01-20 (8-K 2026-08-07). It also left the $3.210M of merger costs in the cost base, printing 18.7x instead of 17.0x, and it read 9.4% revenue growth as quality growth when the filing says it is commodity price pass-through with a 400 basis point gross margin decline.
1. What the business actually does
Nathan's is a brand licensor with a small food distribution arm attached. Three segments: Product licensing, which collected $37.417M of royalties in FY2026, of which $33.589M came from Smithfield Foods at 10.8% of net sales under an agreement running to March 2032 (10-K 2026, Item 1); the Branded Product Program, which sells bulk hot dogs to stadiums, cinemas and travel plazas for $105.768M of revenue; and Restaurant operations, four Company-owned units in New York plus 221 franchised locations and 476 virtual kitchens, contributing $12.508M and $4.317M respectively. The economics are entirely in licensing. In Q1 FY2027, licensing produced $13.541M of the $12.668M of consolidated operating income; Branded Product contributed $1.330M, restaurants $0.920M and corporate cost $3.123M (8-K 2026-08-07). The company employs 129 people.
2. Why it is mispriced, and the honest answer
It is not mispriced. On 2026-01-20 Nathan's signed an Agreement and Plan of Merger with Smithfield Foods and Boardwalk Merger Sub under which Smithfield acquires Nathan's for $102.00 in cash per share, a total enterprise value of about $450M, after which Nathan's ceases to be publicly traded (8-K 2026-08-07). HSR was filed 2026-01-23 and the waiting period expired 2026-02-23. What remains is a stockholder vote and CFIUS clearance, and management now expects closing in the second half of 2026, having pushed the timeline out because a partial government shutdown moved CFIUS statutory deadlines (10-K 2026, Item 1).
So there is no fundamental edge case here. The only edge available is deal-spread underwriting, and that requires information the filing bundle does not contain. The merger agreement itself is not in the bundle, so I cannot read the regulatory-efforts covenants, the outside date, or whether a reverse termination fee exists. The 10-K discloses only a fee payable by Nathan's of $10,581,814, about 2.5% of the equity value, in certain termination circumstances (10-K 2026, Item 1A).
3. The spread, and what the market is saying
Two Form 4s bracket the move. On 2025-12-08, six weeks before announcement, shares withheld from Howard Lorber were valued at $89.87 (Form 4, 2025-12-09). On 2026-06-11, shares withheld from director Andrew Levine were valued at $101.58 (Form 4, 2026-06-12), a spread of 0.4% to the deal price. At the screen's $97.81 the spread is $4.19, or 4.28%. The spread has widened roughly tenfold since June while the disclosed facts have not changed, which is the single most interesting thing in this file and which the filings do not explain.
The buyer's incentive is strong. Smithfield already pays Nathan's $31.893M a year in retail royalties on hot dogs Smithfield itself manufactures (10-K 2026, Item 1). Buying the brand extinguishes that royalty, a 7.2% pre-tax yield on a $441M purchase price before any operating synergy, and removes the 2032 renewal negotiation. The vote is close to a formality: directors and officers held 30.7% and GAMCO a further 12.7% as of 2025-07-21 (DEF 14A 2025-07-25), against a simple majority requirement.
4. Balance sheet and capital allocation
Cash $24.686M at 2026-06-28 against a term loan of roughly $47.6M, amortising $2.4M a year. The merger agreement has closed off every other capital allocation lever: buybacks are prohibited outright, and after the $0.50 regular dividend paid 2026-06-30 the company may declare no further dividends (10-K 2026, Item 7). So there is no income to collect while waiting. FY2026 operating cash flow was $18.234M against $0.370M of capex, but that was struck after $3.2M of deal fees and a $5.9M build in Branded Product receivables.
5. Management: said versus did
Management has said the same three sentences about the merger in every filing since January and has otherwise stopped forecasting. Lorber's employment agreement gives him a change-of-control termination right worth the greater of salary and bonus for the remaining term or 2.99 times salary and bonus, plus an excise tax gross-up (10-K 2026, Item 1A). His interests are aligned with closing.
6. Valuation
Base case: the deal closes by 2026-12-31 for $102.00 cash, a 4.28% gross return in about 111 days, roughly 14% annualised, with no dividends in between. Bear case: CFIUS blocks or the parties walk; the reference point for a standalone price is the $89.87 of December 2025, and fundamentals are worse now than then, with gross margin down 400 basis points and Branded Product segment profit halved, so call it $85 to $88, an 11% to 13% loss. Bull case: clearance comes in October and the return annualises above 30%. Reverse DCF, in the only form that applies to a capped equity: at $97.81 against $102.00, and assuming an $88 break price, the price implies about a 70% probability of closing (65% at a $90 break, 75% at $85). That is a materially lower probability than I would assign to a signed all-cash strategic deal that has already cleared antitrust, but I have no CFIUS-specific information to justify overriding the market, and neither does the filing bundle.
7. Catalysts and timeline
Definitive merger proxy and a stockholder meeting date; a CFIUS clearance or mitigation-agreement announcement; closing, guided to the second half of 2026.
8. Pre-registered kill criteria
- An 8-K disclosing termination of the Merger Agreement, or payment of the $10,581,814 fee. That reopens Nathan's as a standalone fundamental case at a much lower price and I would re-cover it.
- The shares trade below $92 (a spread wider than 10%) while the Merger Agreement remains in force and no 8-K discloses an adverse CFIUS action. That is a genuine arbitrage and would move this to WATCH.
- Branded Product Program segment operating income below $1.0M in any quarter, against $1.330M in Q1 FY2027 and $2.276M a year earlier. That lowers the break-case floor.
- Closing. Coverage ends.
9. Verdict and summary
PASS, conviction 4. Nathan's has been a signed deal since 2026-01-20: Smithfield Foods is buying it for $102.00 a share in cash, about $450M of enterprise value, and the equity cannot be worth more than that. The screen has no merger flag, so it ranked a takeout target as the 60th best quality-growth industrial on 9.4% revenue growth, when the filing says that growth is beef inflation passed straight through at a 400 basis point lower gross margin, with the Branded Product segment's operating income cut 42% in the latest quarter. What is on offer at $97.81 is a 4.28% gross spread on a deal that has cleared HSR and needs only a stockholder vote, which insiders and GAMCO can nearly carry alone, and CFIUS clearance delayed by a government shutdown. That spread has widened tenfold since June without any disclosed change in the facts, and it implies roughly a 70% chance of closing. That may be too pessimistic, given Smithfield is buying out a $31.9M royalty it pays on its own sales, but underwriting a CFIUS review is not a fundamental research judgement and the primary documents contain nothing to price it with. This belongs on a merger-arbitrage desk, not here.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.